A new study conducted by the Center for Health Services Research at Henry Ford Hospital and published in the February issue of the Journal of Clinical Endocrinology & Metabolism, suggests that a certain class of diabetes drugs known as thiazolidinediones may increase the risk of bone fracture in women. While most consumers couldn’t identify thiazolidinediones, they surely would recognize brand name drugs such as Actos and Avandia, two of the more popular members of the diabetes drug class.
The Henry Ford study was restricted to those with Type II diabetes. The findings were striking in that women who took the thiazolidinedione for one year were 50% more likely to experience a bone fracture. Interestingly, thiazolidinedione use in men, regardless of age, did not impact the likelihood of bone fracture.
- Federal Judge Finds Health Insurer DiscriminatedAgainst Patients with Substance Abuse and Mental Health Disorders - March 25, 2019
- Factors Impacting Maternal Health During Hospital Births - March 22, 2019
- Jury Awards $117 million in Johnson & Johnson’sFirst Trial Loss in Asbestos-Related, Talc Powder Lawsuits - April 24, 2018